Theramex Launches Non-hormonal Femarelle® on the 12th of May
Theramex will be joining the 20th International Society of Gynecological Endocrinology (ISGE) congress from the 11th-14th May in Florence, Italy. The ISGE is a non-profit organization whose purpose is to drive more awareness around important gynecology topics ensuring a dialogue between interested parties.
Theramex are very proud to introduce Femarelle® which Theramex will commercialize in Italy, France, Spain, Germany, UK, Belgium, Poland and Australia. Femarelle® is a non-hormonal food supplement developed to help women manage symptoms in perimenopause, with Femarelle® Rejuvenate1; menopause, with Femarelle® Recharge2; and post-menopause, with Femarelle® Unstoppable3.
At Theramex we are committed to supporting women throughout their different stages in life, offering a host of options to suit their specific health needs along the way. As many women with menopause symptoms do not currently use HRT treatment, but instead are choosing lifestyle changes to cope with them, Femarelle® could be another option for these women.
As Camilla Harder Hartvig, Chief Commercial Officer at Theramex says "we are delighted to add Femarelle® to our already broad portfolio of prescription products to treat menopause symptoms. We are all about giving women choices so that they can take charge themselves and through these choices continue to live life uninterrupted".
Theramex is a leading global specialty pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.
1 Femarelle® Rejuvenate package leaflet.
2 Femarelle® Recharge package leaflet.
3 Femarelle® Unstoppable package leaflet.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Camilla Harder Hartvig
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biognosys Announces Appointment of Beat Lüthi, Ph.D., as independent Board Director19.5.2022 14:00:00 CEST | Press release
Biognosys, a leader in next-generation proteomics solutions for life science research and drug development, announced today the appointment of Beat Lüthi, Ph.D., as Board Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005079/en/ Beat Lüthi, Ph.D. – Biognosys' Newly Appointed Board Director. (Photo: Business Wire) Dr. Lüthi is Chief Executive Officer of CTC Analytics AG, a privately owned Swiss company leading in automation and advanced laboratory sample handling solutions for the pharmaceutical, life science, chemical, environmental, and food & flavor industries. Additionally, he holds several Board of Directors mandates in public firms, including Chairman of Inficon Group, Vice Chairman of Straumann Group, and Board Member of Skan AG. Dr. Lüthi holds an M.Sc. in Electrical Engineering and a Ph.D. in Business Administration from ETH Zurich and completed an International Executive Program at the INSEAD Busines
Inversago Pharma Presents Data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress19.5.2022 14:00:00 CEST | Press release
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 59th Congress of the European Renal Association (ERA), the largest annual nephrology meeting in Europe, currently held in Paris, France. These data show that INV-202, the company’s lead peripheral CB1 blocker, reduced renal injury in a murine model of Streptozotocin (STZ)-induced Diabetes. More specifically, INV-202 reduced glomerular injury, renal fibrosis and injury to proximal tubular epithelial cells, and also preserved podocyte structure and function. In particular, there was a marked, dose-dependent reduction in albuminuria in this model of diabetes and associated kidney injury. “The study showed that treatment with INV-202 reduced the progression of nephropathy in STZ-induced diabetic mice. Improvements in kidney size, function, and renal matrix remodeling, with corresponding gene expression were noted with b
Grovara Partners with Dubai Global Connect, Establishes Middle East HQ and Showroom19.5.2022 13:00:00 CEST | Press release
Grovara, the easy global wholesale experience, announces it has signed a lease agreement and become formally incorporated to do business in Dubai as part of a partnership with Dubai Global Connect (DGC), a permanent wholesale market that facilitates business between international buyers and sellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005017/en/ Grovara and Dubai Global Connect cemented their partnership on April 26, 2022 at DGC's new Visitor Centre in Dubai. Standing, from left are Grovara Sales Director Eugenia Schlitter, Grovara Executive Chairman David Pottruck, Grovara Chief Innovation Officer/Co-founder Peter Groverman, Dubai Global Connect Food Business Development Lead Badreddine Soukarie, and Grovara VP of Global Supply Chain Juliana Rogenski; Seated, from left are Dubai Global Connect Head of Business Development Paul Boots and Grovara CEO/Co-founder Abu Kamara. (Photo: Business Wire) The partnersh
Zilliant Launches Quick Start Program to Speed Time to Value and First Quick Start Package, Transforming How Companies Manage Pricing in Response to Inflation19.5.2022 13:00:00 CEST | Press release
Zilliant, the industry leader in intelligent end-to-end pricing solutions and sales guidance software, today announced its Zilliant Quick Start Program, which enables significantly faster deployment times for its software and faster time-to-value for customers. The first Quick Start package of this transformative program is Zilliant Quick Start for Global and Country Price Lists, which is available beginning today. In the past, deploying price optimization and management software may have seemed time intensive or difficult to implement. As a direct result, pricing and commercial teams rely on spreadsheets to manage pricing, sales operations and commercial functions, a method that is insufficient to respond to today’s volatile market conditions. The Zilliant Quick Start program flips this paradigm, offering packaged solutions to address specific pricing and sales challenges, each of which can be up and running within the span of three to eight weeks, work seamlessly with each other on t
Eaton Introduces DC-DC Converters for 48-Volt Commercial Vehicle Architectures19.5.2022 12:30:00 CEST | Press release
Power management company Eaton today introduced a family of 48-volt DC-DC converters for diesel-powered commercial vehicles that can be used to power accessories such as antilock brakes and lighting. Unlike competitive offerings, Eaton’s DC-DC converters are operational in ambient temperatures up to 85 degrees Celsius and boast 97% design efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005093/en/ Eaton’s family of 48-volt DC-DC converters can be used to power accessories such as antilock brakes and lighting and are operational in ambient temperatures up to 85 degrees Celsius. (Graphic: Business Wire) “DC-DC converters are an essential part of our eMobility product portfolio and are used in a variety of vehicle applications,” said Ben Karrer, director, Technology Development, Eaton’s eMobility business. “Many commercial vehicle manufacturers are transitioning to 48-volt architectures, so having the ability to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom